IGC Pharma
IGC
25 hedge funds and large institutions have $943K invested in IGC Pharma in 2024 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 6 reducing their positions, and 6 closing their positions.
36% more capital invested
Capital invested by funds: $692K → $943K (+$252K)
0% more funds holding
Funds holding: 25 → 25 (0)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
0.31% less ownership
Funds ownership: 3.87% → 3.57% (-0.31%)
67% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$43.9K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$9.09K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$5.1K |
| 4 |
Jane Street
New York
|
+$4.53K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$806 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$21.5K |
| 2 |
State Street
Boston,
Massachusetts
|
-$20K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$19.3K |
| 4 |
VF
Virtu Financial
New York
|
-$17K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$7.19K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$21.5K | -76,872 | Closed |
|
|
BCM
27
Bridgeway Capital Management
Houston,
Texas
| – | -$19.3K | -69,000 | Closed |
|
|
VF
28
Virtu Financial
New York
| – | -$17K | -60,723 | Closed |
|
29
JP Morgan Chase
New York
| – | -$1.38K | -4,917 | Closed |
|
30
UBS Group
Zurich,
Switzerland
| – | -$1.33K | -4,747 | Closed |
|
|
GPFA
31
Game Plan Financial Advisors
Westlake,
Ohio
| – | -$140 | -500 | Closed |
|
IGC Hedge Fund Activity: Q1 2024 in Review
25 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in IGC Pharma (IGC) for Q1 2024, worth a combined $943K — up 36% from $692K a quarter earlier.
Fund positioning in IGC was balanced in Q1 2024: 6 funds opened new positions, 6 closed out, 2 added to existing stakes and 6 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $43.9K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $21.5K sold.
- 25 institutional investors held IGC Pharma (IGC) as of Q1 2024, unchanged from Q4 2023.
- Funds reported $943K of IGC Pharma stock for Q1 2024, up 36% quarter-over-quarter.
- 6 funds opened new IGC Pharma positions in Q1 2024 and 6 closed out, a net change of 0 holders.
- The largest IGC Pharma buyer in Q1 2024 was Renaissance Technologies, an estimated $43.9K added.
- The largest IGC Pharma seller in Q1 2024 was Susquehanna International Group, an estimated $21.5K sold.
Based on aggregated 13F filings for Q1 2024.